Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | CHRND | Q07001 | 8/20 | 0.55 |
| ▸ | CHRNA1 | P02708 | 4/20 | 0.55 |
| ▸ | CHRNG | P07510 | 4/20 | 0.55 |
| ▸ | CHRNB1 | P11230 | 4/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.52 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.52 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16485202 | 0.90 | CHRNB2 (0.56) | MMP2CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL17128773 | 0.90 | CHRNB2 (0.56) | MMP2CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL25873942 | 0.89 | CHRNB2 (0.52) | CHRNDCHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL16485208 | 0.89 | MMP2 (0.60) | MMP2CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL25887442 | 0.87 | HDAC3 (0.53) | CHRNDCHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL16485165 | 0.87 | CHRNA1 (0.54) | MMP2CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL38659045 | 0.86 | CHRND (0.59) | MMP2CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL25873928 | 0.86 | CHRNB2 (0.47) | CHRNDCHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL25452475 | 0.86 | OPRD1 (0.51) | MMP2CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL17029474 | 0.86 | CHRNB2 (0.54) | MMP2CHRNDCHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212182-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212182-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | RCC2, REN, VHL | MMP2 456/4885CHRND 4142/4885CHRNA1 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.